Endogenous Peptide Drugs
Naturally occurring peptides like insulin, oxytocin, vasopressin, and calcitonin serve as the basis for important therapeutic agents. These molecules demonstrate how endogenous peptides can be harnessed for medicine.
What Are Endogenous Peptide Drugs?
Endogenous peptide drugs are therapeutic agents derived from or based on peptides that the human body naturally produces. Unlike synthetic drugs designed from scratch, these molecules evolved for specific biological functions. Modern medicine has adapted them as treatments by understanding their natural roles and optimizing them for pharmaceutical use.
Insulin: The First Peptide Drug
Insulin is a 51-amino acid peptide hormone produced by pancreatic beta cells. It regulates blood glucose by promoting cellular uptake of glucose into muscle, fat, and liver cells. Before insulin was available as a drug, type 1 diabetes was fatal.
Today, insulin is produced through recombinant DNA technology. Human insulin is identical to the natural hormone. Modified forms include insulin lispro (rapid-acting), insulin glargine (long-acting), and insulin detemir, which differ by one or two amino acids or modifications that alter absorption kinetics.
Oxytocin: The Bonding Hormone
Oxytocin is a nine-amino acid cyclic peptide produced in the hypothalamus and released by the posterior pituitary. It stimulates uterine contractions during labor and milk ejection during breastfeeding. It also plays roles in social bonding and trust.
Synthetic oxytocin (Pitocin) is used clinically to induce labor and control postpartum hemorrhage. The peptide contains a disulfide bridge between two cysteine residues, forming a six-residue ring that is essential for receptor binding.
Vasopressin: Water Balance
Vasopressin (antidiuretic hormone, ADH) is a nine-amino acid peptide similar in structure to oxytocin. It promotes water reabsorption in the kidneys and raises blood pressure through vasoconstriction.
Desmopressin (DDAVP) is a synthetic analog with two modifications: deamino at position 1 and D-arginine at position 8. These changes extend its half-life from about 20 minutes to 12 hours, making it practical for treating diabetes insipidus and nocturnal enuresis.
Calcitonin: Bone Protection
Calcitonin is a 32-amino acid peptide produced by thyroid C cells. It inhibits osteoclast activity, reducing calcium release from bones. Salmon calcitonin is more potent than human calcitonin and is used to treat osteoporosis and Pagets disease.
Mnemonic: “IOVC” for Key Endogenous Peptide Drugs
Remember the four major examples with “IOVC”: Insulin (glucose), Oxytocin (contraction), Vasopressin (water), Calcitonin (bone).
Practical Insight
Endogenous peptide drugs face challenges including short half-life, poor oral bioavailability, and immunogenicity. Modern pharmaceutical science addresses these through PEGylation, cyclization, non-natural amino acid substitution, and formulation in depot preparations. Understanding the natural peptide is the first step toward engineering a better drug.